Archford Capital Strategies’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-347
Closed -$32K 571
2019
Q2
$32K Buy
347
+75
+28% +$7.12K 0.01% 307
2019
Q1
$26K Buy
272
+200
+278% +$17.5K 0.01% 313
2018
Q4
$5K Sell
72
-1,289
-95% -$95.2K ﹤0.01% 409
2018
Q3
$122K Sell
1,361
-225
-14% -$19.9K 0.04% 234
2018
Q2
$126K Buy
1,586
+398
+34% +$33K 0.04% 236
2018
Q1
$124K Buy
+1,188
New +$114K 0.05% 151
2017
Q3
Sell
-1,883
Closed -$245K 205
2017
Q2
$245K Buy
1,883
+9
+0.5% +$1.1K 0.1% 172
2017
Q1
$233K Sell
1,874
-264
-12% -$31.6K 0.09% 185
2016
Q4
$247K Sell
2,138
-145
-6% -$16.1K 0.1% 159
2016
Q3
$238K Hold
2,283
0.1% 170
2016
Q2
$225K Buy
+2,283
New +$236K 0.12% 142
2016
Q1
Sell
-1,126
Closed -$135K 760
2015
Q4
$135K Buy
1,126
+261
+30% +$30.2K 0.06% 195
2015
Q3
$94K Sell
865
-223
-20% -$27.7K 0.07% 154
2015
Q2
$126K Hold
1,088
0.09% 137
2015
Q1
$125K Buy
1,088
+244
+29% +$29.2K 0.09% 142
2014
Q4
$94K Buy
844
+200
+31% +$21.1K 0.07% 158
2014
Q3
$61K Buy
+644
New +$58.1K 0.05% 190
2014
Q2
Sell
-102
Closed -$7.12K 979
2014
Q1
$7.12K Buy
+102
New +$8.08K 0.01% 486

Other funds holding CELG

Archford Capital Strategies's CELG Position: Q3 2019 in Review

Archford Capital Strategies sold out of Celgene Corp (CELG) in Q3 2019, closing a stake of 347 shares — an estimated $32K sold.

Archford Capital Strategies first reported a position in CELG in Q1 2014 and held it in 18 quarters. The position peaked at $247K in Q4 2016. 1,245 funds tracked by Wall St. Rank hold CELG as of Q3 2019.

  • Archford Capital Strategies reported no remaining Celgene Corp position as of Q3 2019 after selling out during the quarter.
  • Archford Capital Strategies sold 347 Celgene Corp shares in Q3 2019, an estimated $32K.
  • Archford Capital Strategies first reported a position in Celgene Corp in Q1 2014 and held it in 18 quarters.
  • Archford Capital Strategies's Celgene Corp position peaked at $247K in Q4 2016.
  • 1,245 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2019.

Based on Archford Capital Strategies's 13F filing for Q3 2019, filed 23 Oct 2019.